Elon Musk Unveils $30k-$50k/Year AI Passive Income Stream for Millions of Americans
Dear Reader,
During Tesla's last earnings call, Elon Musk quietly unveiled a new way to use AI – and he says it could create a substantial passive income stream.
According to the New York Sun, Elon reports that users "will soon be able to make money while they sleep."
U.S. Senator Ted Cruz calls it "a total game-changer."
And fellow congressman John Cornyn says it's "remarkable."
Elon estimates that you could make $30,000-$50,000 a year with minimal effort and modest upfront costs.
Millions of Americans are eligible to participate.
However, you must start now to ensure you don't miss out.
This is a brand-new business model, and the folks who get in front of it could potentially make a lot of money.
To learn how you can take advantage of this cutting-edge passive income stream, check out our free full presentation here.
Regards,
Luis Hernandez
Editor in Chief, InvestorPlace
Blue Owl's Risk/Reward Profile Is Almost Too Good to Be True
Reported by Sam Quirke. First Published: 3/29/2026.
Key Points
- Blue Owl Capital shares have collapsed more than 65% from last year’s highs, pushing the stock close to all-time lows.
- The selloff has been driven by fears around private credit and the SaaSpocalypse, but recent analyst upgrades suggest those concerns may be overdone.
- With a 10% dividend yield and expectations at rock bottom, the risk/reward profile looks increasingly attractive.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Blue Owl Capital Inc. (NYSE: OWL), an alternative asset manager, has been making headlines for all the wrong reasons lately.
Shares are trading around $9, down more than 65% from their highs last year and over 40% since the start of this year. It's not a high-growth tech stock, though the recent price action might suggest otherwise.
Why "Canadian Gold" crushes ordinary gold and stocks (Ad)
Gold surged from $2,063 in January 2024 to an all-time high of $5,595 in January 2026 - but 'Canadian Gold' left ordinary gold, silver, the NASDAQ, and the S-P 500 in the dust.
Known as 'the Warren Buffett of Canada,' one of the world's most connected investors is loading up on this asset. Find out what Canadian Gold is and why it has outperformed since inception.
Click here to discover what Canadian Gold is and why it outperformsFor a company in the private credit space that specializes in loans to software companies, a decline of this magnitude raises worrying questions — and, as we'll see below, investor fears have some justification. They're right to ask whether something is fundamentally broken, but at the same time a growing group of voices is calling the selloff a screaming buy opportunity.
Let's take a closer look at what's driving the drop and how real this opportunity might be.
What Spooked Investors
The multi-month selloff in Blue Owl shares has largely been driven by weakening sentiment in private credit and the sharp downturn in traditional software stocks, which comprise much of Blue Owl's borrower base. As we've been highlighting, software names have faced intense pressure to prove they can navigate disruption from AI.
Many have seen growth trajectories flatten and shares fall to multi-year lows. As a major lender to these companies, Blue Owl is exposed when its borrowers run into trouble.
Risk appetite has deteriorated further amid geopolitical tensions in the Middle East, making investors particularly sensitive to signs of stress in credit markets. If defaults rise or liquidity tightens, firms like Blue Owl would face pressure on both asset values and fundraising. Add growing concerns that the company might limit investor redemptions, and it's easy to see why the stock has been sold aggressively.
The Fundamentals Are Stable
There is, however, an argument that the market may have overreacted. Blue Owl's fee-based model, supported by long-duration capital, provides earnings visibility that many financial firms lack. Unlike more transactional businesses, a substantial portion of its revenue is less dependent on short-term market activity.
The dividend is another point in its favor. It has a four-year track record of increases and currently offers a yield of around 10%. For income-focused investors, that yield makes the stock hard to ignore.
Analysts Are Turning Bullish
Perhaps the most telling shift recently has been a change in analyst sentiment. After several downgrades earlier this year, Blue Owl is now collecting bullish ratings from firms such as BMO Capital Markets and TD Cowen, both of which reiterated Buy-equivalent ratings this week. Those calls echo Oppenheimer's bullish view earlier this month and suggest market fears about private credit and AUM growth may be overblown relative to the company's performance.
Refreshed price targets reinforce that view — some, like Citizens JMP's $23 target, imply more than 150% upside from current levels. That disconnect between price and expectation is rare and suggests the stock's risk/reward profile may be skewed toward the bulls.
Sizing up the Opportunity
That said, Blue Owl still trades at a price-to-earnings ratio above 80, which is elevated by most standards and well above many peers.
Heading into next month's earnings report, that valuation creates risk. Expectations are low, but with a frothy P/E there could be additional downside if results disappoint. In other words, while the chart may make the stock look cheap relative to prior levels, it isn't necessarily cheap on an absolute basis.
If Blue Owl can demonstrate steady AUM growth, reaffirm dividend stability, and dispel fears about liquidity, the upside could be sizable. After a decline this severe, it wouldn't take much to trigger a sharp reversal — particularly given recent analyst updates that imply as much as 150% upside.
The Often-Missed Corner of Healthcare That Wall Street Is Loving
Author: Nathan Reiff. Posted: 3/29/2026.
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to post some of the market's wildest spikes and drops. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach, focusing on companies that supply essential equipment and services rather than higher-risk pharmaceutical names.
Lab equipment stocks are often overlooked, even though some companies in this subindustry rank among the largest in healthcare. With a range of external factors likely to influence healthcare companies in 2026—shifting subsidies, an aging population with growing needs, inflation, the expanding role of AI, and more—core lab equipment names could be especially attractive. The companies below are some of the major players worth a closer look.
A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Why "Canadian Gold" crushes ordinary gold and stocks (Ad)
Gold surged from $2,063 in January 2024 to an all-time high of $5,595 in January 2026 - but 'Canadian Gold' left ordinary gold, silver, the NASDAQ, and the S-P 500 in the dust.
Known as 'the Warren Buffett of Canada,' one of the world's most connected investors is loading up on this asset. Find out what Canadian Gold is and why it has outperformed since inception.
Click here to discover what Canadian Gold is and why it outperforms$182-billion life-sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a challenging start to 2026, with shares down more than 15% year-to-date (YTD) and the stock recently slipping into TradeSmith's red zone for financial health. A sizable portion of that weakness appears related to tariffs and FX volatility, which together compressed margins by more than 100 basis points in 2025.
That said, there are several bright spots in Thermo Fisher's recent performance.
In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also exceeded forecasts at $6.57.
Some of that momentum likely reflects recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings.
Thermo Fisher's broad business model and diversified product portfolio could provide a cushion against external pressures. Even if 2026 guidance is conservative—revenue projected to grow 4% to 6%—expected improvements to EBITDA margin and persistently strong customer demand are positive signs. That may explain why, despite the pullback, analysts remain supportive: 17 of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside potential.
Danaher's Business May Be Improving, Even as Guidance Remains Modest
Danaher Corp. (NYSE: DHR) is also trading lower—down nearly 20% YTD—as the instruments, consumables, and reagents firm navigates a similar environment to Thermo Fisher. Although 2026 guidance points to modest core revenue growth of 3% to 6% YOY, the latest quarter delivered a top- and bottom-line beat and the company generated $5.3 billion in free cash flow for 2025.
Two key bright spots for 2026 are Danaher's bioprocessing business—expected to generate high-single-digit revenue growth driven by strong monoclonal antibody demand—and diagnostics.
Diagnostics should benefit from recent FDA clearances, while equipment orders have begun to recover after a prolonged slump, which could further support sales.
Analysts are reasonably optimistic on DHR, forecasting roughly 12.3% earnings growth over the next year and about 35% upside in the share price.
That optimism is reflected in ratings: 19 of 22 analysts rate DHR shares as Buys.
Agilent's Biocare Purchase Could Be a Catalyst
Agilent Technologies (NYSE: A) has lagged the peers above based on its latest results, which showed only 4.4% YOY revenue growth and slight misses on both revenue and earnings versus expectations.
However, Agilent may have a new growth driver in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics.
Although the deal cost nearly $1 billion, Biocare should add recurring revenue in an area with rising demand. Cancer diagnostics can also carry higher margins than some of Agilent's existing lines, which could help improve operating margins (Agilent's operating margin was 24.6% in the most recent quarter).
Despite a roughly 17% YTD decline, analysts see potential upside of about 42% for Agilent shares. Wall Street's consensus is a Moderate Buy, with 13 of 16 analysts rating the stock a Buy or equivalent.
This email communication is a paid advertisement sent on behalf of InvestorPlace, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions or concerns about your newsletter, feel free to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. United States..
